Fundraising Fox

DepYmed

Farmingdale, US · Delaware corporation

DepYmed is a biotech company developing orally bioavailable small-molecule inhibitors of the enzyme PTP1B and copper-chelating compounds as therapeutics for cancer, rare diseases, and conditions such as Rett Syndrome and Wilson Disease. Its pipeline targets protein tyrosine phosphatase signaling pathways implicated in metabolic, inflammatory, and neurodegenerative diseases.

BiotechHealthtech

Founders & leadership

AGAndreas G. Grill
Andreas G. GrillExecutive

Board

LG
Leo GuthartBoard director
SB
Samuel BackenrothBoard director
SH
Shankar HariharanBoard director
PY
Peter YoungBoard director
SW
Steve WinickBoard director

Reported raises · per SEC filings

Form D private placements

$9.2M disclosed across 6 rounds · 2021–2025

▶$250KraisedApr 2025 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Shankar HariharanDirector
  • Leo GuthartDirector
  • Steve WinickDirector
  • Peter YoungDirector
  • Andreas G. GrillExecutive Officer, Director
Offering amount
$250K
Amount sold
$250K
First sale
Apr 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$250KraisedFeb 2025 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Peter YoungDirector
  • Andreas G. GrillExecutive Officer, Director
  • Steve WinickDirector
  • Shankar HariharanDirector
  • Leo GuthartDirector
Offering amount
$250K
Amount sold
$250K
First sale
Jan 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$600KraisedAug 2024 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Shankar HariharanDirector
  • Andreas G. GrillExecutive Officer, Director
  • Peter YoungDirector
  • Steve WinickDirector
  • Leo GuthartDirector
Offering amount
$600K
Amount sold
$600K
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$500KraisedMar 2024 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Andreas G. GrillExecutive Officer, Director
  • Steve WinickDirector
  • Leo GuthartDirector
  • Peter YoungDirector
  • Shankar HariharanDirector
  • Peter Van NessExecutive Officer
Offering amount
$500K
Amount sold
$500K
First sale
Mar 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedMay 2023 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Shankar HariharanDirector
  • Leo GuthartDirector
  • Peter YoungDirector
  • Steve WinickDirector
  • Andreas G. GrillExecutive Officer, Director
  • Peter Van NessExecutive Officer
Offering amount
$2M
Amount sold
$2M
First sale
Mar 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.5MraisedApr 2021 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Steve WinickDirector
  • Andreas G. GrillExecutive Officer, Director
  • Samuel BackenrothDirector
  • Leo GuthartDirector
  • Shankar HariharanDirector
  • Peter YoungDirector
Offering amount
$15M
Amount sold
$5.5M
Placement agents
Rainmaker Securities, LLC, Catalytic Life Sciences, Inc.
First sale
Apr 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Insmed3 shared keywordsInsmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.
Phormed3 shared keywordsPhorMed develops next-generation therapies targeting inflammation-driven diseases, particularly rare oncological conditions, using AI-powered targeting technology. The company serves patients with inflammatory and cancer-related diseases, focusing on improving efficacy and safety of first-line treatments.

Companies competing with DepYmed for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

DepYmed to Meet with Investors at the BIO CEO and Investor Conferencefinance.yahoo.com · Feb 2024DepYmed to Meet with Investors at the Life Sciences Summit in New York City October 11, 2023finance.yahoo.com · Oct 2023Long Island drug startup snares $8.3 million in venture funding - Newsdaynewsday.com · Apr 2021DepYmed snags $100,000 to develop new breast cancer drug - Newsdaynewsday.com · Dec 2015

Frequently asked questions

What does DepYmed do?
DepYmed is a biotech company developing orally bioavailable small-molecule inhibitors of the enzyme PTP1B and copper-chelating compounds as therapeutics for cancer, rare diseases, and conditions such as Rett Syndrome and Wilson Disease. Its pipeline targets protein tyrosine phosphatase signaling pathways implicated in metabolic, inflammatory, and neurodegenerative diseases.
How much funding has DepYmed raised?
DepYmed has disclosed $9.2M raised across 6 rounds.
Where is DepYmed headquartered?
DepYmed is headquartered in Farmingdale, US.